{"id":"NCT01866319","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)","officialTitle":"A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Patients With Advanced Melanoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-08-28","primaryCompletion":"2015-03-03","completion":"2019-06-03","firstPosted":"2013-05-31","resultsPosted":"2016-01-14","lastUpdate":"2020-06-02"},"enrollment":834,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Melanoma"],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab","otherNames":["MK-3475"]},{"type":"BIOLOGICAL","name":"Ipilimumab","otherNames":[]}],"arms":[{"label":"Ipilimumab","type":"EXPERIMENTAL"},{"label":"Pembrolizumab Q2W","type":"EXPERIMENTAL"},{"label":"Pembrolizumab Q3W","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate the safety and efficacy of 2 different dosing schedules of pembrolizumab (MK-3475), every 2 weeks (Q2W) and every 3 weeks (Q3W), and compare the 2 schedules to treatment with ipilimumab in ipilimumab-na√Øve participants with unresectable or metastatic melanoma. The primary hypotheses are that pembrolizumab is superior to ipilimumab with respect to progression-free survival (PFS) and overall survival (OS).","primaryOutcome":{"measure":"Progression-free Survival (PFS) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Independent Radiology Plus Oncology Review (IRO)","timeFrame":"Up to approximately 12 months (through first pre-specified statistical analysis cut-off date of 03-Sep-2014)","effectByArm":[{"arm":"Ipilimumab","deltaMin":2.8,"sd":null},{"arm":"Pembrolizumab Q2W","deltaMin":5.5,"sd":null},{"arm":"Pembrolizumab Q3W","deltaMin":4.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.00001"},{"comp":"OG000 vs OG002","p":"<0.00001"},{"comp":"OG001 vs OG002","p":"0.75869"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":16},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["28822576","39306585","37348035","34571336","33360855","32305010","31395089","31345627","30736858","30202085","30096704","28987768","25891173"],"seeAlso":["http://merckoncologyclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":77,"n":256},"commonTop":["Fatigue","Diarrhoea","Nausea","Pruritus","Constipation"]}}